Sunday, July 16, 2017 2:36:27 PM
Award-winning platform, outstanding pre-clinical with proven MOAs and targets, strong team, multi-billion dollar markets for both lead compounds consisting of several potential indications.
Will have 3-4 candidates in clinic by end of 2018, 2 internal and 1-2 with partners (Merck KgaA and/or Takeda). Recent IPO (June) with steady flow of milestones (up to $2B) from partnerships.
Looking at a 5-year 10-bagger here...good luck to all.
Will post often here.
Recent MRSN News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:09 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 09:06:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:10:47 AM
- Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 10:59:33 AM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 08:30:15 PM
- Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:42 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/04/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:08:40 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 09:07:03 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/28/2024 09:05:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 01:49:00 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 02/28/2024 01:43:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:07:49 PM
- Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 12:00:08 PM
- Mersana Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/27/2024 01:01:15 PM
- Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 • GlobeNewswire Inc. • 02/21/2024 01:00:22 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:56:11 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:43:32 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:20:00 PM
- Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/01/2024 01:00:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:21:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:20:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:19:56 PM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM